Cell therapies have suffered from hyped-up expectations, clinical setbacks and high costs. But maybe, just maybe, Arovella is ...

The advent of a Trump presidency is accelerating a divergence on digital currencies between the world’s two largest economies ...

ASX tech rocked a 50pc gain in 2024, Archer Materials shone in December, and Dubber and Brainchip have cashed in on major ...

Neurizon recently received EMA orphan designation for NUZ-001 to treat ALS and filed an FDA IND application to begin a phase ...

Ads for AI-related roles are shrinking in Australia, new job data reveals, with the number down 35 per cent compared to over ...

Stockhead's Sarah Hughan unpacks clinical stage biotech company AdAlta, set to unlock value from its AD-214 asset and expand its pipeline through its "East to West" cell therapy strategy in 2025.

Gold outshined the chasing pack as only a handful of commodities sailed through choppy economic waters unscathed in a ...

Morningstar’s analyst picks ResMed and PWR as top ASX long-term plays, with ResMed eyeing sleep market domination.

With pending news flow of significance coming in 2025, these ASX-listed gas companies could be worth putting on your radar.

Percheron Therapeutics' board of directors has written a letter to shareholders following failure of its phase 2b trial.